Magazine Article | October 3, 2022

Companies To Watch: CytoAgents

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader
Follow Me On Twitter @WayneKoberstein

Combatting the broad areas of disease stemming from a common cause: cytokine release syndrome


CytoAgents primarily focuses on developing a single lead drug, coded CTO1681, in multiple indications involving cytokine release syndrome (CRS). Simply stated, CRS is “an overreaction of the immune system, commonly known as cytokine storm.” It has many causes and affects many areas and systems of the body. CTO1681 targets the NF-kB (nuclear factor kappa B) signaling pathway to modulate cytokine production, thus reducing inflammation. NF-kB is a protein transcription factor that regulates innate immunity as well as gene expression that controls inflammation. CytoAgents has early programs in four areas: oncology (with CAR T-cell therapy), dermatology (atopic dermatitis), neurology (traumatic brain injury), and infectious disease (respiratory and COVID-19).

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader